At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 400 target
Drug / intervention
Jaktinib Hydrochloride Tabletdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Extended Clinical Trial of Long-term Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Jaktinib Hydrochloride Tablet for Atopic Dermatitis. Targeting 400 participants across 2 sites.
Detailed Summary
To observe the safety and effectiveness of long-term use of jaktinib hydrochloride tablets in the treatment of moderate and severe atopic dermatitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesChina
Collaborators--
Timeline
Phase 3UnknownOverdue
2023202420252026
First PostedJan 2023
Enrollment StartJan 2023
Primary CompletionDec 2024
TodayJul 2026
First PostedJan 9, 2023
Enrollment StartJan 11, 2023
Primary CompletionDec 1, 2024
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 3.5 years ago
Interventions
Jaktinib Hydrochloride Tabletdrug
Orally administered, twice a day